Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116571828> ?p ?o ?g. }
- W2116571828 abstract "This study was designed to mainly evaluate the activity and safety of olanzapine compared with 5-hydroxytryptamine 3(5-HT3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly or moderately emetogenic chemotherapy (HEC or MEC). The second goal was to evaluate the impact of olanzapine on quality of life (QoL) of cancer patients during the period of chemotherapy.229 patients receiving highly or moderately emetogenic chemotherapy were randomly assigned to the test group [olanzapine(O) 10 mg p.o. plus azasetron (A) 10 mg i.v. and dexamethasone (D) 10 mg i.v. on day 1; O 10 mg once a day on days 2-5] or the control group (A 10 mg i.v. and D 10 mg i.v. on day 1; D 10 mg i.v. once a day on days 2-5). All the patients filled the observation table of CINV once a day on days 1-5, patients were instructed to fill the EORTC QLQ-C30 QoL observation table on day 0 and day 6. The primary endpoint was the complete response (CR) (without nausea and vomiting, no rescue therapy) for the acute period (24 h postchemotherapy), delayed period (days 2-5 postchemotherapy), the whole period (days 1-5 postchemotherapy). The second endpoint was QoL during chemotherapy administration, drug safety and toxicity.229 patients were evaluable for efficacy. Compared with control group, complete response for acute nausea and vomiting in test group had no difference (p > 0.05), complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 39.21% (69.64% versus 30.43%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 25.01% (83.07% versus 58.06%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with highly emetogenic chemotherapy respectively improved 41.38% (69.64% versus 28.26%, p < 0.05), 22.05% (78.57% versus 56.52%, p < 0.05), complete response for the whole period of nausea and vomiting in patients with moderately emetogenic chemotherapy respectively improved 26.62% (83.07% versus 56.45%, p < 0.05), 13.43% (89.23% versus 75.80%, p < 0.05). 214 of 299 patients were evaluable for QoL. Comparing test group with control group in QoL evolution, significant differences were seen in global health status, emotional functioning, social functioning, fatigue, nausea and vomiting, insomnia and appetite loss evolution in favour of the test group (p < 0.01). Both treatments were well tolerated.Olanzapine can improve the complete response of delayed nausea and vomiting in patients receiving the highly or moderately emetogenic chemotherapy comparing with the standard therapy of antiemesis, as well as improve the QoL of the cancer patients during chemotherapy administration. Olanzapine is a safe and efficient drug for prevention of CINV." @default.
- W2116571828 created "2016-06-24" @default.
- W2116571828 creator A5003693447 @default.
- W2116571828 creator A5010479652 @default.
- W2116571828 creator A5028124343 @default.
- W2116571828 creator A5045340917 @default.
- W2116571828 creator A5046581028 @default.
- W2116571828 creator A5047788407 @default.
- W2116571828 creator A5056084219 @default.
- W2116571828 date "2009-09-23" @default.
- W2116571828 modified "2023-10-13" @default.
- W2116571828 title "Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting" @default.
- W2116571828 cites W1984152751 @default.
- W2116571828 cites W1987963303 @default.
- W2116571828 cites W1994776603 @default.
- W2116571828 cites W2000759429 @default.
- W2116571828 cites W2020758186 @default.
- W2116571828 cites W2027393266 @default.
- W2116571828 cites W2028568939 @default.
- W2116571828 cites W2029309368 @default.
- W2116571828 cites W2045951807 @default.
- W2116571828 cites W2049330440 @default.
- W2116571828 cites W2068927187 @default.
- W2116571828 cites W2072532597 @default.
- W2116571828 cites W2113208497 @default.
- W2116571828 cites W2143726677 @default.
- W2116571828 cites W2153119854 @default.
- W2116571828 cites W2165395427 @default.
- W2116571828 cites W3012248373 @default.
- W2116571828 doi "https://doi.org/10.1186/1756-9966-28-131" @default.
- W2116571828 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2761865" @default.
- W2116571828 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19775450" @default.
- W2116571828 hasPublicationYear "2009" @default.
- W2116571828 type Work @default.
- W2116571828 sameAs 2116571828 @default.
- W2116571828 citedByCount "140" @default.
- W2116571828 countsByYear W21165718282012 @default.
- W2116571828 countsByYear W21165718282013 @default.
- W2116571828 countsByYear W21165718282014 @default.
- W2116571828 countsByYear W21165718282015 @default.
- W2116571828 countsByYear W21165718282016 @default.
- W2116571828 countsByYear W21165718282017 @default.
- W2116571828 countsByYear W21165718282018 @default.
- W2116571828 countsByYear W21165718282019 @default.
- W2116571828 countsByYear W21165718282020 @default.
- W2116571828 countsByYear W21165718282021 @default.
- W2116571828 countsByYear W21165718282022 @default.
- W2116571828 countsByYear W21165718282023 @default.
- W2116571828 crossrefType "journal-article" @default.
- W2116571828 hasAuthorship W2116571828A5003693447 @default.
- W2116571828 hasAuthorship W2116571828A5010479652 @default.
- W2116571828 hasAuthorship W2116571828A5028124343 @default.
- W2116571828 hasAuthorship W2116571828A5045340917 @default.
- W2116571828 hasAuthorship W2116571828A5046581028 @default.
- W2116571828 hasAuthorship W2116571828A5047788407 @default.
- W2116571828 hasAuthorship W2116571828A5056084219 @default.
- W2116571828 hasBestOaLocation W21165718281 @default.
- W2116571828 hasConcept C118552586 @default.
- W2116571828 hasConcept C126322002 @default.
- W2116571828 hasConcept C2776412080 @default.
- W2116571828 hasConcept C2776619155 @default.
- W2116571828 hasConcept C2776694085 @default.
- W2116571828 hasConcept C2779924295 @default.
- W2116571828 hasConcept C2780580376 @default.
- W2116571828 hasConcept C2780852908 @default.
- W2116571828 hasConcept C2780884295 @default.
- W2116571828 hasConcept C42219234 @default.
- W2116571828 hasConcept C71924100 @default.
- W2116571828 hasConceptScore W2116571828C118552586 @default.
- W2116571828 hasConceptScore W2116571828C126322002 @default.
- W2116571828 hasConceptScore W2116571828C2776412080 @default.
- W2116571828 hasConceptScore W2116571828C2776619155 @default.
- W2116571828 hasConceptScore W2116571828C2776694085 @default.
- W2116571828 hasConceptScore W2116571828C2779924295 @default.
- W2116571828 hasConceptScore W2116571828C2780580376 @default.
- W2116571828 hasConceptScore W2116571828C2780852908 @default.
- W2116571828 hasConceptScore W2116571828C2780884295 @default.
- W2116571828 hasConceptScore W2116571828C42219234 @default.
- W2116571828 hasConceptScore W2116571828C71924100 @default.
- W2116571828 hasIssue "1" @default.
- W2116571828 hasLocation W21165718281 @default.
- W2116571828 hasLocation W21165718282 @default.
- W2116571828 hasLocation W21165718283 @default.
- W2116571828 hasLocation W21165718284 @default.
- W2116571828 hasOpenAccess W2116571828 @default.
- W2116571828 hasPrimaryLocation W21165718281 @default.
- W2116571828 hasRelatedWork W2119857165 @default.
- W2116571828 hasRelatedWork W2334156963 @default.
- W2116571828 hasRelatedWork W2468214969 @default.
- W2116571828 hasRelatedWork W2972346832 @default.
- W2116571828 hasRelatedWork W3127491962 @default.
- W2116571828 hasRelatedWork W3209644827 @default.
- W2116571828 hasRelatedWork W4306407785 @default.
- W2116571828 hasRelatedWork W4362662114 @default.
- W2116571828 hasRelatedWork W4382581927 @default.
- W2116571828 hasRelatedWork W2338742873 @default.
- W2116571828 hasVolume "28" @default.
- W2116571828 isParatext "false" @default.
- W2116571828 isRetracted "false" @default.
- W2116571828 magId "2116571828" @default.